Exactly. The investigator doesn’t need to run a trial on their own. It is a lot more work for them to run an investigator initiated trial than put their patients into a company sponsored trial. There is no lack of sponsored AML trials in Australia, so they could have saved themselves a great deal of hassle by not approaching us. They have only done this because they have seen what Bisantrene can do and they think it will help their patients. Great for the patients and great for Race and all us shareholders.
Ann: Updated Strategy and Investor Presentation, page-342
- There are more pages in this discussion • 167 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.01 |
Change
0.260(14.9%) |
Mkt cap ! $350.7M | |||
| Open | High | Low | Value | Volume |
| $1.87 | $2.08 | $1.86 | $1.028M | 525.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 16735 | $2.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.02 | 1355 | 2 |
View Market Depth
| Last trade - 14.12pm 18/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.00 |
Change
0.260 ( 15.1 %) |
||||
| Open | High | Low | Volume | ||
| $1.86 | $2.08 | $1.86 | 34111 | ||
| Last updated 14.29pm 18/06/2024 ? | |||||
| RAC (ASX) Chart |